Previously reported MRD negative CR in 2 of 3 relapsed/refractory AML patients enrolled in first dose level and schedule of Phase 1 clinical trial of SENTI-202 maintaining remission – – Strengthened ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback